Please login to the form below

Not currently logged in
Email:
Password:

Kim Lemon appointed head of Liberation Unlimited

Will lead rebrand of Communiqué award-winning agency
Kim Lemon, Liberation

Liberation Unlimited has named former associate director Kim Lemon as its new head.

The announcement comes a few weeks after Liberation Communications changed its name to Liberation Unlimited as part of a rebrand of its parent group Creston Health, which is now known as Health Unlimited.

Lemon spent five years as associate director at Liberation having joined the company in 2009 from Athena Medical PR where she served as senior account manager. She also has experience in industry at the Johnson & Johnson subsidiary Lifescan.

Catherine Warne, CEO of Health Unlimited said: “Over the last year, and particularly in the last five months, Kim has become a figurehead for the agency.

“She has taken the lead on the development of a strong business plan for the agency, the roll-out of Liberation Unlimited and completely fresh branding, which will be launched in the New Year.” 

During her time at Liberation Lemon helped the agency to the Small Consultancy or Health Team of the Year award at the 2014 Communiqué Awards. She also led the PR team that won the Cello Health Award for Launch Excellence at the recent PMEA for its work on Bayer's Eylea.

11th December 2014

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...